MARKHAM, Ontario - TelAve -- Virotek Biosciences Inc., a leading Canadian  genomic company, today announced the installation and commissioning of the AVITI24™ 5D multi-omic system from Element Biosciences Inc., marking the first commercial deployment of this  first-of-its-kind multi-omics  platform in Canada.

The AVITI24 system delivers exceptional sequencing throughput, accuracy, and cost efficiency, redefining the economics of high-performance genomics. Its dual-flow-cell design enables flexible run configurations and parallel sequencing, providing laboratories with greater scalability and shorter turnaround times without compromising data quality.

This milestone positions Virotek at the forefront of translational and multi-omic research, integrating AVITI24's revolutionary 5D multi-omic technology, which enables simultaneous capture of RNA, protein, morphology, spatial context, and dynamic response from a single sample. The AVITI24 system is the first commercially available, fully integrated platform capable of generating such comprehensive biological insights without traditional library preparation steps.

More on TelAve News

• Starlink Local Installers getting Iowa connected
• Kentucky Judges Ignore Evidence, Prolong Father's Ordeal in Baseless Case
• Contracting Resources Group Receives 2025 HIRE Vets Platinum Medallion Award from the U.S. Department of Labor
• Crunchbase Ranks Phinge Founder & CEO Robert DeMaio #1 Globally. Meet him in Las Vegas-Week of CES to Learn About Netverse, Patented App-less Platform
• IODefi Introduces New Web3 Infrastructure Framework as XRP Ledger Development Gains Global Attention

"This advancement represents a defining moment for genomic and translational research in Canada," said Saeid Babaei, PhD, Chief Visionary Officer of Virotek Biosciences. "We believe this investment enables us to deliver faster, more scalable, and more cost-efficient NGS to our clients, while preserving the high data quality our genomic workflows demand."

"Virotek's adoption of AVITI24 marks a meaningful step in Element's mission to expand access to innovative multi-omic technologies worldwide," said Danae Van Oene, senior vice president of global sales and support at Element Biosciences. "Through companies like Virotek, AVITI24 is extending its impact globally—enabling new discoveries and greater clarity about human biology."

This deployment enhances Virotek's ability to support whole genome, exome, targeted panels, and molecular profiling research within a scalable infrastructure built for growth. In addition to improved per-sample economics and turnaround times, Virotek expects the AVITI24 to strengthen its internal R&D capacity, reduce dependency on external sequencing providers, and accelerate its roadmap for new genomic and multi-omic assay development.

More on TelAve News

• Terizza Forms Strategic Collaboration with UC San Diego to Pioneer Next-Generation Distributed AI Infrastructure
• EnergyStrat Launches Global LNG Risk Outlook 2025–2030
• Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
• Holiday Decorations Most Likely to Cause Injuries
• UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System

To learn more about Element, please visit www.virotekbio.com and follow us on LinkedIn (https://www.linkedin.com/company/virotek-biosciences/).